Cargando…

Dissecting the Immune Landscape of Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a molecularly heterogeneous hematological malignancy with variable response to treatment. Recurring cytogenetic abnormalities and molecular lesions identify AML patient subgroups with different survival probabilities; however, 50–70% of AML cases harbor either normal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davidson-Moncada, Jan, Viboch, Elena, Church, Sarah E., Warren, Sarah E., Rutella, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316310/ https://www.ncbi.nlm.nih.gov/pubmed/30477280 http://dx.doi.org/10.3390/biomedicines6040110

Ejemplares similares

S129: ADOPTIVELY INFUSED MEMORY-LIKE (ML) NATURAL KILLER (NK) CELLS ELICIT ADAPTIVE IMMUNE RESPONSES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
por: Rutella, Sergio, et al.
Publicado: (2023)

The Epigenetic Landscape of Acute Myeloid Leukemia
por: Conway O'Brien, Emma, et al.
Publicado: (2014)

Genomic landscape of hyperleukocytic acute myeloid leukemia
por: Largeaud, Laetitia, et al.
Publicado: (2022)

Molecular landscape and targeted therapy of acute myeloid leukemia
por: Gu, Runxia, et al.
Publicado: (2018)

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia
por: Ragaini, Simone, et al.
Publicado: (2022)

Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2020)

Targeting Leukemia Stem Cells in the Bone Marrow Niche
por: Tasian, Sarah K., et al.
Publicado: (2018)

The clinical impact of the molecular landscape of acute myeloid leukemia
por: Kayser, Sabine, et al.
Publicado: (2023)

DHH-RHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3-GLIS2-positive acute myeloid leukemia
por: Masetti, Riccardo, et al.
Publicado: (2013)

Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia
por: Ahmadmehrabi, Khashayar, et al.
Publicado: (2021)

The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia
por: Bănescu, Claudia, et al.
Publicado: (2023)

Functional Genomic Landscape of Acute Myeloid Leukemia
por: Tyner, Jeffrey W., et al.
Publicado: (2018)

A Panorama of Immune Fighters Armored with CARs in Acute Myeloid Leukemia
por: Christodoulou, Ilias, et al.
Publicado: (2023)

Proteomic and phosphoproteomic landscapes of acute myeloid leukemia
por: Kramer, Michael H., et al.
Publicado: (2022)

Harnessing Immune Response in Acute Myeloid Leukemia
por: Riva, Carola, et al.
Publicado: (2023)

Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia
por: Higgins, Alexandra, et al.
Publicado: (2020)

Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia
por: Barwe, Sonali P., et al.
Publicado: (2022)

Redirecting the Immune Microenvironment in Acute Myeloid Leukemia
por: Sendker, Stephanie, et al.
Publicado: (2021)

Molecular landscape in acute myeloid leukemia: where do we stand in 2016
por: Al-Issa, Karam, et al.
Publicado: (2016)

Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia
por: Rutella, Sergio, et al.
Publicado: (2022)

Early Palliative Care in Acute Myeloid Leukemia
por: Potenza, Leonardo, et al.
Publicado: (2022)

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
por: Alves, Raquel, et al.
Publicado: (2021)

Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia
por: Giannopoulos, Krzysztof
Publicado: (2019)

Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Kapoor, Sargam, et al.
Publicado: (2021)

Immune-Based Therapeutic Strategies for Acute Myeloid Leukemia
por: Böhme, Matthias, et al.
Publicado: (2021)

Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies
por: Hou, Hsin-An, et al.
Publicado: (2020)

Current Landscape of Genome-Wide Association Studies in Acute Myeloid Leukemia: A Review
por: Marrero, Richard J., et al.
Publicado: (2023)

The mutational landscape of atypical chronic myeloid leukemia
por: Langabeer, Stephen E.
Publicado: (2019)

Deciphering the Non-Coding RNA Landscape of Pediatric Acute Myeloid Leukemia
por: Vanhooren, Jolien, et al.
Publicado: (2022)

The triggering receptor expressed on myeloid cells (TREM) in inflammatory bowel disease pathogenesis
por: Genua, Marco, et al.
Publicado: (2014)

The modular network structure of the mutational landscape of Acute Myeloid Leukemia
por: Ibáñez, Mariam, et al.
Publicado: (2018)

Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications
por: Marando, Ludovica, et al.
Publicado: (2020)

The immunometabolic landscape of the bone marrow microenvironment in acute myeloid leukemia
por: Xu, Binyan, et al.
Publicado: (2022)

P424: LANDSCAPE OF CHROMATIN ACCESSIBILITY IN ACUTE MYELOID LEUKEMIA
por: Ochi, Yotaro, et al.
Publicado: (2023)

Acute Myeloid Leukemia Mutations: Therapeutic Implications
por: Papayannidis, Cristina, et al.
Publicado: (2019)

Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy
por: Khaldoyanidi, Sophia, et al.
Publicado: (2021)

Emerging therapies for acute myeloid leukemia
por: Saygin, Caner, et al.
Publicado: (2017)

PB1823: SECONDARY ACUTE MYELOID LEUKEMIA AND DE NOVO ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED CHANGES DISTINCT LANDSCAPE, OR THE SAME DISEASE?
por: Jagurinoski, M., et al.
Publicado: (2022)

Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance
por: Lachowiez, Curtis A., et al.
Publicado: (2023)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_38h8t8hktkagm5hlb9ir9gh3r6